Podcast: Innovating Autoimmune Treatment With In Vivo CAR-T

As the promise of in vivo CAR-T therapy moves steadily toward clinical reality, biotech innovators are redefining the boundaries of what may be possible in autoimmune disease. Driven by rapid scientific progress, more precise engineering tools, and evolving regulatory frameworks, this emerging generation of cell therapies has the potential to fundamentally reshape how immune-mediated conditions are treated — shifting the focus from chronic management to targeted, durable immune reset.

In this episode, Pete Robinson, Therapeutic Strategy Director at Novotech, joins Meredith Landry, Managing Editor of Custom Content at Citeline, to examine how in vivo CAR-T technology is opening new therapeutic frontiers for autoimmune disorders—and what the field must accomplish to convert early scientific promise into meaningful patient outcomes.

Together, they discuss:

• The transformative potential of in vivo CAR-T therapy

How direct, in-body CAR-T cell engineering could overcome key limitations of ex vivo approaches and emerge as a true game-changer for autoimmune care.

• Scientific, clinical, and operational considerations for success

Critical factors—including vector design, safety strategies, dose optimization, and trial execution—that will influence the ability to advance programs through early development.

• The global landscape for early-phase trials

Where innovation is accelerating, how regulators are approaching this new modality, and what sponsors should consider when planning first-in-human and proof-of-concept studies.

If you’re working at the intersection of cell therapy, immunology, and biotech innovation, this conversation provides timely insights into where the field is heading and how to position your programs at the forefront of the next wave of autoimmune therapeutics.